📊 GNPX Key Takeaways
Is Genprex, Inc. (GNPX) a Good Investment?
Genprex is a pre-revenue pharmaceutical company burning $3.1M quarterly with only $18M in cash, providing approximately 18 months of operational runway. While the balance sheet is clean with minimal debt and excellent liquidity, the lack of revenue combined with ongoing operational losses reflects a high-risk biotech venture entirely dependent on uncertain clinical trial outcomes and regulatory success.
Genprex is a pre-revenue biotech with persistent operating losses (~$15.5M) and deeply negative ROE/ROA, indicating no clear path to profitability. Although debt-free with a strong current ratio, its ~$7.8M cash covers less than a year of burn, implying likely near-term financing and dilution. On fundamentals alone, risk outweighs strengths until clinical milestones unlock funding or revenue.
Genprex, Inc. Key Strengths (GNPX)
- Strong cash position of $18.0M providing adequate near-term liquidity
- Minimal debt with Debt/Equity ratio of 0.00x and clean balance sheet structure
- Excellent current ratio of 5.61x demonstrating strong ability to meet short-term obligations
- Debt-free balance sheet with low liabilities and high current ratio
- Cash position sufficient for near-term obligations
- Capex-light model enabling focus on R&D
GNPX Stock Risks: Genprex, Inc. Investment Risks
- Pre-revenue company with zero revenue and $4.5M quarterly operating losses
- Quarterly cash burn of $3.1M limits operational runway to approximately 18 months without additional capital
- High-risk biotech model with uncertain clinical trial results and lengthy regulatory approval timelines
- Short cash runway versus operating burn, creating high dilution risk
- No revenue and continued operating losses with negative returns on capital
- Clinical/regulatory execution risk delaying commercialization
Key Metrics to Watch
- Quarterly cash burn trend and remaining months of runway
- Clinical trial milestones and regulatory submission progress
- Capital raise activities and equity dilution impact on shareholders
- Quarterly operating cash flow and cash runway
- Clinical/approval milestones and partnership or grant funding
Genprex, Inc. (GNPX) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Strong liquidity with a 5.61x current ratio provides a solid financial cushion.
GNPX Profit Margin, ROE & Profitability Analysis
GNPX vs Healthcare Sector: How Genprex, Inc. Compares
How Genprex, Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Genprex, Inc. Stock Overvalued? GNPX Valuation Analysis 2026
Based on fundamental analysis, Genprex, Inc. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Genprex, Inc. Balance Sheet: GNPX Debt, Cash & Liquidity
GNPX Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Genprex, Inc.'s revenue has remained relatively flat over the 5-year period, with a 0% decline. The most recent EPS of $-266.89 indicates the company is currently unprofitable.
GNPX Revenue Growth, EPS Growth & YoY Performance
GNPX Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2022 | N/A | -$3.4M | $-0.07 |
| Q2 2022 | N/A | -$4.0M | $-0.08 |
| Q1 2022 | N/A | -$5.7M | $-0.12 |
| Q3 2021 | N/A | -$2.8M | N/A |
| Q2 2021 | N/A | -$4.0M | N/A |
| Q1 2019 | N/A | -$694.0K | N/A |
| Q3 2018 | N/A | -$715.1K | N/A |
| Q2 2018 | N/A | -$1.2M | N/A |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Genprex, Inc. Dividends, Buybacks & Capital Allocation
GNPX SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Genprex, Inc. (CIK: 0001595248)
📋 Recent SEC Filings
❓ Frequently Asked Questions about GNPX
What is the AI rating for GNPX?
Genprex, Inc. (GNPX) has a Combined AI Grade of C from Claude (C) and ChatGPT (D) with 79% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are GNPX's key strengths?
Claude: Strong cash position of $18.0M providing adequate near-term liquidity. Minimal debt with Debt/Equity ratio of 0.00x and clean balance sheet structure. ChatGPT: Debt-free balance sheet with low liabilities and high current ratio. Cash position sufficient for near-term obligations.
What are the risks of investing in GNPX?
Claude: Pre-revenue company with zero revenue and $4.5M quarterly operating losses. Quarterly cash burn of $3.1M limits operational runway to approximately 18 months without additional capital. ChatGPT: Short cash runway versus operating burn, creating high dilution risk. No revenue and continued operating losses with negative returns on capital.
What is GNPX's revenue and growth?
Genprex, Inc. reported revenue of $0.0.
Does GNPX pay dividends?
Genprex, Inc. does not currently pay dividends.
Where can I find GNPX SEC filings?
Official SEC filings for Genprex, Inc. (CIK: 0001595248) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is GNPX's EPS?
Genprex, Inc. has a diluted EPS of $0.00.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined grade reflects both perspectives for balanced insights.
What is GNPX's fundamental grade?
Based on our AI fundamental analysis in May 2026, Genprex, Inc. has a C grade with 79% confidence. Review the strengths and risks sections above for full context. This is not investment advice.
Is GNPX stock overvalued or undervalued?
Valuation metrics for GNPX: ROE of -26.4% (sector avg: 15%), net margin of N/A (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
What is GNPX's AI grade for 2026?
Our dual AI analysis gives Genprex, Inc. a combined C grade for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is GNPX's free cash flow?
Genprex, Inc.'s operating cash flow is $-3.1M, with capital expenditures of $0.0.
How does GNPX compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin N/A (avg: 12%), ROE -26.4% (avg: 15%), current ratio 5.61 (avg: 2).